Creatinine

IDEXX Announces Novel Diagnostic Test for Kidney Injury, Expanding the Veterinary Industry's Most Comprehensive Renal Testing Portfolio

Retrieved on: 
Thursday, June 15, 2023
Cystatin, Laboratory, Chronic kidney disease, Urine, Creatinine, Veterinarian, Acute kidney injury, Urology, Idexx Laboratories, Biomarker, Patient, IDXX, Nephrology, Dog, Kidney, Diagnosis, Cystatin B, American College, Health, CKD, Kidney disease, Founding, Cat, Dietary supplement, Pharmaceutical industry, Phosphorus, Veterinary medicine

WESTBROOK, Maine, June 15, 2023 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the launch of the first veterinary diagnostic test for detecting kidney injury in cats and dogs. According to a recent IDEXX survey, as many as one-third of kidney cases seen by veterinarians are related to kidney injury, and a diagnosis can be challenging due to subtle or nonspecific signs.1 The IDEXX Cystatin B Test will be included in test panels assessing renal health, uncovering new clinical insights for an estimated two million patient visits annually. These tests will be run at IDEXX Reference Laboratories starting later this year in the U.S. and Canada, with plans to introduce the test in Europe in 2024.

Key Points: 
  • Together, the IDEXX Cystatin B and IDEXX SDMA® tests offer a comprehensive view of the kidneys by uncovering structural injury and impaired kidney function.
  • The IDEXX expanded renal testing portfolio now includes:
    IDEXX Cystatin B Test, detecting kidney injury with or without changes in kidney function, providing valuable insights in cases such as early toxin exposure.
  • IDEXX SDMA® Test and creatinine, helping to establish a baseline for kidney function for monitoring and early kidney disease detection.
  • For more information on the IDEXX Cystatin B Test and IDEXX kidney health solutions, please visit IDEXX Cystatin B .

IMFINZI® (durvalumab) plus chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MATTERHORN Phase III trial

Retrieved on: 
Friday, June 2, 2023
Pharmaceutical, Health, Oncology, Clinical Trials, Dicarboxylic acid, Docetaxel, Infection, Radiation, IVA, FLOT, Vall d'Hebron University Hospital, Creatinine, Oxaliplatin, Pneumonitis, Adrenocorticotropic hormone, Doctor of Philosophy, AstraZeneca, PCR, Administration, Prednisone, Incidence, MD, Patient, GEJ, Immune system, Cancer, EFS, Warning, ACTH, Stomach, III, Safety, Medical imaging, Pharmaceutical industry, Vaccine, EU

These results demonstrate an increase in pathologic complete response after adding durvalumab treatment to FLOT chemotherapy and surgery.

Key Points: 
  • These results demonstrate an increase in pathologic complete response after adding durvalumab treatment to FLOT chemotherapy and surgery.
  • Immune‑mediated pneumonitis occurred in 1.3% (5/388) of patients receiving IMFINZI and IMJUDO, including fatal (0.3%) and Grade 3 (0.2%) adverse reactions.
  • Immune-mediated colitis occurred in 2% (37/1889) of patients receiving IMFINZI, including Grade 4 (
  • Immune‑mediated colitis or diarrhea occurred in 6% (23/388) of patients receiving IMFINZI and IMJUDO, including Grade 3 (3.6%) adverse reactions.

Renalytix selects EVERSANA® to expand commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes

Retrieved on: 
Thursday, May 25, 2023
Insurance, LSE, Glycated hemoglobin, Kidney failure, Additive effect, American Diabetes Association, Chronic kidney disease, Diabetes, Creatinine, The American Journal of Managed Care, Type 2 diabetes, Prognosis, Community health, Journal, American Journal, Patient, Risk, Kidney, UACR, Artificial intelligence, Diabetic nephropathy, Kidney disease, Pharmaceutical industry

Using highly reliable, bioprognostic™ methodology, KidneyIntelX yields a simple-to-understand, custom risk score, helping clinicians better predict which adult patients with type 2 diabetes may be at various stages of chronic kidney disease.

Key Points: 
  • Using highly reliable, bioprognostic™ methodology, KidneyIntelX yields a simple-to-understand, custom risk score, helping clinicians better predict which adult patients with type 2 diabetes may be at various stages of chronic kidney disease.
  • “We believe that patients deserve the best options every day in their healthcare journey,” said Jim Lang, CEO at EVERSANA.
  • “The majority of people with type 2 diabetes over the age of 65 have chronic kidney disease,” said James McCullough, CEO of Renalytix.
  • Additional real-world KidneyIntelX utility data is expected to be released at the American Diabetes Association annual clinical meeting this June.

IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) and IMFINZI alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy

Retrieved on: 
Friday, May 26, 2023
Environment, Climate Change, FDA, Other Health, Biotechnology, Managed Care, General Health, Pharmaceutical, Health, Oncology, Infection, Endometrial cancer, Radiation, University, Progression-free survival, Creatinine, Cancer, Gynecologic Oncology (journal), Woman, Pneumonitis, MD Anderson Cancer Center, Adrenocorticotropic hormone, Immunotherapy, AstraZeneca, PFS, Administration, Prednisone, Death, Incidence, Patient, Physician, Warning, Reproductive medicine, PARP, ACTH, Pharmaceutical industry, Vaccine

Immune-mediated colitis occurred in 2% (37/1889) of patients receiving IMFINZI, including Grade 4 (

Key Points: 
  • Immune-mediated colitis occurred in 2% (37/1889) of patients receiving IMFINZI, including Grade 4 (
  • Immune‑mediated colitis or diarrhea occurred in 6% (23/388) of patients receiving IMFINZI and IMJUDO, including Grade 3 (3.6%) adverse reactions.
  • Immune-mediated adrenal insufficiency occurred in 1.5% (6/388) of patients receiving IMFINZI and IMJUDO, including Grade 3 (0.3%) adverse reactions.
  • In patients with extensive-stage SCLC in the CASPIAN study receiving IMFINZI plus chemotherapy (n=265), IMFINZI was discontinued due to adverse reactions in 7% of the patients receiving IMFINZI plus chemotherapy.

scPharmaceuticals Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, May 10, 2023
Hypersensitivity, Furosemide, NYHA, Congestion, Embolism, Medicaid, Hypoproteinemia, Organic acid, Heart failure, AT, Urine, Pharmacy, Creatinine, Cirrhosis, Dehydration, Tinnitus, Glucose, Heart, Deafness, Huber loss, Edema, Food and Drug Administration, Hepatic encephalopathy, Medicare Part D, Prescription, Research, Part, Oliguria, History, Trial of the century, Diuresis, Uric acid, Medicare, New York Heart Association Functional Classification, Kidney, Bruise, Ototoxicity, Erythema, Investment, Physician, Patient, Urinary retention, Azotemia, Ascites, Coma, Blood volume, Benign prostatic hyperplasia, Therapy, Thrombosis, Cerebral edema, BUN, CO2, Conference, Food, Anuria, Security (finance), Pharmaceutical industry, Health insurance, Video game, Medical device, BURLINGTON

BURLINGTON, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the first quarter ended March 31, 2023, and provided a business update. 

Key Points: 
  • Ended the first quarter of 2023 with cash, cash equivalents and short-term investments of $116.1 million.
  • Net product revenues were $2.1 million and cost of product revenues were $0.6 million for the first quarter of 2023.
  • Research and development expenses were $2.1 million for the first quarter of 2023, compared to $4.3 million for the first quarter of 2022.
  • As of March 31, 2023, scPharmaceuticals’ total shares outstanding was 35,769,073.
    scPharmaceuticals’ management will host a conference call and webcast to review the Company’s first quarter 2023 results today, Wednesday, May 10, at 4:30 p.m.

Marizyme, Inc.: Marizyme Announces IP Developments for DuraGraft® and its Pipeline of Products

Retrieved on: 
Wednesday, May 10, 2023
LLP, CE, Chronic kidney disease, Private law, Creatinine, Endovascular aneurysm repair, Enzyme, Burn, IP, Incidence, Ischemia, Patent, Epithelium, Growth, Dentons, Skin, Disease, Pharmaceutical industry

The issued patents and allowed patent applications protect DuraGraft, a first-in-class CE marked intra-operative graft storage solution used during bypass surgeries.

Key Points: 
  • The issued patents and allowed patent applications protect DuraGraft, a first-in-class CE marked intra-operative graft storage solution used during bypass surgeries.
  • DuraGraft is the only approved product to preserve and protect vascular grafts during bypass and other vascular surgeries.
  • The patent application relates to a method for mixing two reagents to produce a detectable reaction in a microfluidic chip.
  • Dentons has been consistently ranked for the past years as a top leading life sciences and health care law firm.

Marizyme Announces IP Developments for DuraGraft® and Its Pipeline Products

Retrieved on: 
Wednesday, May 10, 2023
LLP, CE, Chronic kidney disease, Private law, Creatinine, Enzyme, IP, US, Patent, Growth, Dentons, Disease, Pharmaceutical industry

It is considered an investigational product in the United States and is not yet authorized for use in the United States.

Key Points: 
  • It is considered an investigational product in the United States and is not yet authorized for use in the United States.
  • Another patent application covering Marizyme’s Krillase™ enzyme technology was recently allowed in Europe resulting in additional patent protection.
  • The patent application relates to a method for mixing two reagents to produce a detectable reaction in a microfluidic chip.
  • Marizyme’s global patent and IP portfolio is managed by Dentons US LLP , the world’s largest law firm with hundreds of patent lawyers and IP professionals in more than 80 countries.

EyeCare Partners’ Leadership and Clinical Research to be Showcased at American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Retrieved on: 
Thursday, May 4, 2023
Surgery, Health, Science, Research, Optical, Dark, Partner, Eye drop, Ophthalmology, ASCRS, Varenicline, Telecanthus, Patient satisfaction, Ciclosporin, Patient experience, ECP, Presbyopia, Ageing, Randomness, Cataract, Legacy Devers Eye Institute, Wonderful, Manual, Refractive surgery, Endothelium, Ocular hypertension, American Society of Cataract and Refractive Surgery, Somatosensory system, Ketamine, Contact lens, Political moderate, Learning curve, Pilocarpine, DED, Retina, Midazolam, Phacoemulsification, Corneal neovascularization, Loteprednol, Immunosuppression, Physician, Pivotal, Society, Treatment, Rejuvenation, Veterinary medicine, Nursing, Hospital, Telescopic sight, Medical imaging, Pharmaceutical industry, Casino, PRK, Tacrolimus, LASIK, Creatinine, History, Patient

The annual meeting will take place May 5-8, 2023, in San Diego.

Key Points: 
  • The annual meeting will take place May 5-8, 2023, in San Diego.
  • The breadth of topics being presented at ASCRS by ECP physicians emphasizes the company’s culture of innovation and continuous learning.
  • It also underscores the possibility of a career “third pathway” which allows physicians to conduct industry-leading research while also continuing to build a clinical practice.
  • “EyeCare Partners has a strong representation of ophthalmologists presenting research at ASCRS this year, in addition to one of our specialists, Dr. Elizabeth Yeu, serving as the incoming president of ASCRS,” said David Clark, CEO of EyeCare Partners.

Sequana Medical announces FDA clearance of IND application for DSR® 2.0 for treatment of congestive heart failure

Retrieved on: 
Tuesday, May 2, 2023
Overload, NYHA, Congestion, US Foods, PD, Heart failure, DSMB, Hospital, Heart, Creatinine, Liver disease, Peritoneal dialysis, Cancer, Natriuresis, New York Heart Association Functional Classification, DSR, Ethics, Patient, Data, Brussels Stock Exchange, FDA, IND, Food, Safety, RED, Pharmaceutical industry

MOJAVE study on track to start in Q2 2023 as planned, with initial data by year-end

Key Points: 
  • MOJAVE study on track to start in Q2 2023 as planned, with initial data by year-end
    Ghent, Belgium – 02 May 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for its second-generation DSR product (DSR 2.0) for the treatment of congestive heart failure.
  • This enables the Company to initiate its randomized controlled Phase 1/2a MOJAVE study in the US, in Q2 2023 as planned.
  • Oliver Gödje, Chief Medical Officer of Sequana Medical, commented: “We are delighted to obtain clearance of the IND for our DSR 2.0 product and are ready to commence the MOJAVE study in US patients with congestive heart failure in a timely manner.
  • Exploratory endpoints measured from baseline through the end of the treatment period include change in weight (volume status), creatinine (a marker of renal function), natriuretic peptides (a marker of heart failure) and New York Heart Association (NYHA) functional class; and the number of heart failure related rehospitalizations.

IMFINZI-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial

Retrieved on: 
Sunday, April 16, 2023
Oncology, Health, Surgery, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Infection, Radiation, Creatinine, Pneumonitis, PTS, Administration, Prednisone, Incidence, Patient, Warning, FA, Cochran–Mantel–Haenszel statistics, Vaccine

Grade 3/4 any-cause adverse events occurred in 42.3% of patients treated with the IMFINZI-based regimen versus 43.4% for chemotherapy alone.

Key Points: 
  • Grade 3/4 any-cause adverse events occurred in 42.3% of patients treated with the IMFINZI-based regimen versus 43.4% for chemotherapy alone.
  • Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month.
  • Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy.
  • AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.